[Long-term lamivudine therapy for interferon-alpha- and/or adenine arabinoside monophosphate-resistant chronic hepatitis B infection. Results of a pilot study].
Tran
A
A
Longo
F
F
Saint-Paul
M C
MC
Doglio
A
A
Benzaken
S
S
Rampal
P
P
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome; D001084:Vidarabine Phosphate / Q000627:therapeutic use*
D000998:Antiviral Agents; D016898:Interferon-alpha; D001084:Vidarabine Phosphate; D019259:Lamivudine